Log in

NYSE:QGENQiagen Stock Price, Forecast & News

$42.51
-0.20 (-0.47 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$42.48
Now: $42.51
$42.94
50-Day Range
$42.06
MA: $43.13
$44.36
52-Week Range
$25.04
Now: $42.51
$44.41
Volume529,928 shs
Average Volume907,948 shs
Market Capitalization$9.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.32
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, an application for analysis and interpretation of human sequencing data generated with next-generation sequencing (NGS) technologies; QIAGEN Clinical Insight, an evidence-based variant classification; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and order bioinformatics solutions and linking biological interpretation from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; QIAsymphony SP for sample preparation; QIAsymphony AS for assay setup; Rotor-Gene Q, a rotary real-time PCR cycler system; QIAstat-Dx for molecular analysis of common syndromes; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; NeuMoDx 288 and NeuMoDx 96 for automation of higher-throughput PCR testing in clinical laboratories; and QIAcube and QIAcube connect workstations, which provides versatile solutions for automated sample processing; It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has collaboration agreements with Ares Genetics and Laboratory Corporation of America Holdings. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Read More
Qiagen logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.86 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone31-77-355-6600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.53 billion
Cash Flow$2.66 per share
Book Value$11.14 per share

Profitability

Net Income$-41,460,000.00

Miscellaneous

Employees5,096
Market Cap$9.68 billion
Next Earnings Date7/22/2020 (Estimated)
OptionableOptionable

Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.

Qiagen (NYSE:QGEN) Frequently Asked Questions

How has Qiagen's stock been impacted by COVID-19 (Coronavirus)?

Qiagen's stock was trading at $41.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, QGEN stock has increased by 3.4% and is now trading at $42.51. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Qiagen?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 1 sell rating, 14 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Qiagen.

When is Qiagen's next earnings date?

Qiagen is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Qiagen.

How were Qiagen's earnings last quarter?

Qiagen NV (NYSE:QGEN) issued its quarterly earnings data on Wednesday, May, 6th. The company reported $0.34 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.27 by $0.07. The company earned $372.10 million during the quarter, compared to the consensus estimate of $342.71 million. Qiagen had a negative net margin of 2.01% and a positive return on equity of 13.80%. The firm's quarterly revenue was up 6.7% compared to the same quarter last year. During the same period last year, the business posted $0.27 earnings per share. View Qiagen's earnings history.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its second quarter earnings guidance on Tuesday, May, 5th. The company provided earnings per share guidance of at least $0.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.30.

What price target have analysts set for QGEN?

21 Wall Street analysts have issued 1-year target prices for Qiagen's shares. Their forecasts range from $28.00 to $48.00. On average, they expect Qiagen's stock price to reach $37.00 in the next twelve months. This suggests that the stock has a possible downside of 13.0%. View analysts' price targets for Qiagen.

Has Qiagen been receiving favorable news coverage?

Media coverage about QGEN stock has trended somewhat negative recently, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Qiagen earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news about Qiagen.

Are investors shorting Qiagen?

Qiagen saw a decline in short interest in June. As of June 15th, there was short interest totaling 3,360,000 shares, a decline of 8.7% from the May 31st total of 3,680,000 shares. Based on an average daily trading volume, of 1,450,000 shares, the short-interest ratio is presently 2.3 days. Approximately 1.5% of the shares of the company are sold short. View Qiagen's Current Options Chain.

Who are some of Qiagen's key competitors?

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Pfizer (PFE), Twitter (TWTR), Micron Technology (MU), Paypal (PYPL), QUALCOMM (QCOM), Boeing (BA) and Alibaba Group (BABA).

Who are Qiagen's key executives?

Qiagen's management team includes the following people:
  • Mr. Peer Michael Schatz, CEO, MD & Member of Management Board (Age 53)
  • Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 50)
  • Dr. Barthold Piening, Sr. VP & Head of Global Operations (Age 61)
  • Mr. John Gilardi, VP of Corp. Communications & Investor Relations
  • Mr. Jean-Pascal Viola, Head of Corp. Bus. Devel., Intellectual Property & Litigation and Sr. VP

What is Qiagen's stock symbol?

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

How do I buy shares of Qiagen?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $42.51.

How big of a company is Qiagen?

Qiagen has a market capitalization of $9.68 billion and generates $1.53 billion in revenue each year. The company earns $-41,460,000.00 in net income (profit) each year or $1.43 on an earnings per share basis. Qiagen employs 5,096 workers across the globe.

What is Qiagen's official website?

The official website for Qiagen is www.qiagen.com.

How can I contact Qiagen?

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.